Literature DB >> 18088071

A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations.

Agustín Lahoz1, Maria Teresa Donato, Sandra Montero, José V Castell, Maria José Gómez-Lechón.   

Abstract

Primary hepatocytes are still the best qualified in vitro system to anticipate drug metabolism in man. Recent advances in hepatocytes cryopreservation have notably increased their use not only for drug metabolism studies, but also for other applications such as cell transplantation. Evaluation of the drug-metabolizing competence of each hepatocytes preparation is needed. To date, the metabolic characterization of hepatocytes preparations relies on the assessment of phase I activities and the role of phase II enzymes receives little attention. A novel approach for the rapid assessment of the metabolic functionality of hepatocytes has been developed. A five-probe cocktail was used to simultaneously determine the enzymatic activities of major human phase I CYPs (CYP1A2, CYP2A6, CYP2C9, CYP2E1, CYP3A4), as well as two phase II enzymes: glucuronidase (UGTs) and sulfotransferase (SULT). Liquid chromatography/tandem mass spectrometry was used as the technique of choice for the determination of the enzymatic activities in a single run. Results showed that the method described herein permits a rapid assessment of the metabolic capabilities of human hepatocyte preparations as well as an estimation of the quality of freshly isolated or cryopreserved hepatocytes. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18088071     DOI: 10.1002/rcm.3359

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  8 in total

1.  LC/MS evaluation of metabolism and membrane transport of bombesin peptides.

Authors:  Dongyu Gu; Ying Ma; Gang Niu; Yongjun Yan; Lixin Lang; Haji Akber Aisa; Haji Akber Aisaand; Haokao Gao; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-07-30       Impact factor: 3.520

2.  Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.

Authors:  Fazleen H M Hatta; Lay Kek Teh; Anders Helldén; Karin Engström Hellgren; Hyung-Keun Roh; Mohd Zaki Salleh; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

3.  Metabolism and disposition of a novel antineoplastic JS-38 (Benzamide, N-[4-(2,4-dimethoxyphenyl)-4,5-dihydro-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl]-3,5-bis (trifluoromethyl)-(9Cl)) in rats.

Authors:  Hong Zhang; Quanhai Liu; Tingting Fan; Yu Fang; Ying Li; Guoping Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-07-30       Impact factor: 2.441

4.  A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS.

Authors:  Venkateswaran C Pillai; Stephen C Strom; Steve N Caritis; Raman Venkataramanan
Journal:  J Pharm Biomed Anal       Date:  2012-10-22       Impact factor: 3.935

Review 5.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 6.  Applications of LC-MS in PET radioligand development and metabolic elucidation.

Authors:  Ying Ma; Dale O Kiesewetter; Lixin Lang; Dongyu Gu; Xiaoyuan Chen
Journal:  Curr Drug Metab       Date:  2010-07       Impact factor: 3.731

7.  Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes.

Authors:  Elena S Suvorova; Olivier Lucas; Carla M Weisend; Maryclare F Rollins; Gary F Merrill; Mario R Capecchi; Edward E Schmidt
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

8.  Simultaneous determination of cytochrome P450 1A, 2A and 3A activities in porcine liver microsomes.

Authors:  Monika Johansson; Jana Tomankova; Shengjie Li; Galia Zamaratskaia
Journal:  Interdiscip Toxicol       Date:  2012-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.